Bayer (ETR:BAYN) said yesterday that the FDA approved a supplemental biologics license application for the BetaConnect Navigator and myBetaApp – software for its electronic BetaConnect auto-injector.
The company’s BetaConnect auto-injector administers Betaseron for patients with relapsing-remitting multiple sclerosis. The newly-approved software allows patients to connect their device with the myBetaApp on their mobile device or computer and share data with their healthcare team.
“Since introducing the 1st FDA approved treatment option for relapsing remitting multiple sclerosis patients more than 2 decades ago, we’ve listened closely to the community to understand their needs and how we can support them,” Mark Rametta, Bayer’s medical director for neurology, said in prepared remarks. “The myBetaApp and BetaConnect Navigator add to the services that we’ve developed based on patient feedback, including 24/7 access to nurse support and the 1st and only electronic auto-injector for patients taking Betaseron.”
Patients using other injection methods with Betaseron can manually enter injection data into the app and share it with their healthcare team, according to Bayer.
“The MyBetaApp and BetaConnect Navigator work cohesively together to support communication and connection between people living with relapsing remitting multiple sclerosis and their Beta-Nurse and health care team,” Dr. Daniel Kantor, president emeritus of Florida Society of Neurology, said.
